

UK Economics Weekly

How Big is Political Risk in Fiscal Policy?

- This week's note aims to assess the political risks over fiscal policy, both before and after the election (scheduled for 7 May). Our key point is that, despite escalating political rhetoric, fiscal policy differences between the parties are relatively small. All major parties support the Charter for Budget Responsibility (CBR), and they all share a general consensus in favour of deficit reduction, a lower public spending/GDP ratio, and a falling debt/GDP ratio.
- In our view, the key difference between Labour and Conservatives is over whether to emphasise tax cuts or extra public spending once the CBR targets (cyclically adjusted current balance and falling debt/GDP ratio) have been met (hopefully in 2-3 years' time), rather than whether to implement enough fiscal consolidation to achieve the CBR targets. In our view, Labour's fiscal plans do not pose a significantly greater risk to the fiscal outlook for 2015-20 than those of the Conservatives or Lib Dems. There are still political risks for the UK, but these centre on business tax and regulation (in the event of a Labour-led government) or the UK's EU membership (in the event of a Conservative-led government).

Michael Saunders

+44-20-7986-3299

michael.saunders@citi.com

Ann O'Kelly

+44-20-7986-3297


ann.okelly@citi.com

Figure 1. Citi Monetary Policy Forecasts

| | Mid-2015 | End-2015 | End-2016 | End-2017 |
|-----------|----------|----------|----------|----------|
| Base Rate | 0.50 | 0.75 | 2.00 | 3.00 |
| QE Target | £375bn | £375bn | £315bn | £315bn |

Source: Citi Research

Figure 2. UK — Fiscal Deficit Outlook Under Alternative Fiscal Policies, Pct of GDP, 2013/14-2019/20



Note: Fiscal policy scenarios detailed inside, all based on OBR figures for nominal GDP and tax revenues.

Sources: OBR and Citi Research

See Appendix A-1 for Analyst Certification, Important Disclosures and non-US research analyst disclosures.

Citi Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Certain products (not inconsistent with the author's published research) are available only on Citi's portals.

Assessing Fiscal Risks

As we [discussed last week](#), there are major uncertainties over the outcome of the election (scheduled for 7 May). Opinion polls consistently point to a doubly hung parliament, ie neither the Conservatives nor Labour will have a parliamentary majority, and the Lib Dems will not have enough MPs to hold the balance of power. In our view, the most likely government in this scenario would be a left-leaning “rainbow coalition” (including Labour, the SNP, Lib Dems and perhaps also the Greens and Plaid Cymru), with the next most likely outcome being a right-leaning minority coalition of the Conservatives and Lib Dems -- with UKIP giving support on a case by case basis but not formally in the coalition. This week’s note aims to assess the political risks over fiscal policy, both before and after the election.

We stress a key caveat. None of the political parties have yet published their manifesto, which would usually give a definitive list of policy proposals. For all of the parties it is possible to construct a long list of fiscal policy aims and aspirations which have been floated at some point in the last few years, but which probably would not in practice be priorities in government. We focus on specific policy proposals made recently by each party’s leader and finance spokesman, specific pledges on the main pages of each party’s web site, and (where available) published fiscal plans.

Charter for Budget Responsibility

The key constraint on the fiscal policies of all parties will be the updated Charter for Budget Responsibility (CBR), which on 13 Jan 2015 was voted through Parliament with strong support from all major parties. This commits the government to:

- A forward-looking aim to achieve cyclically-adjusted current balance (ie deficit ex investment) by the end of the third year of the rolling, 5-year forecast period. With public investment at 1.5% of GDP now and (on the current coalition plans) 1.2% of GDP in 17/18 onwards, this rule would allow modest overall budget deficits of up to 1.2% of GDP per year for 2017/18 onwards.
- A supplementary aim for public sector net debt as a share of GDP to be falling in 2016-17. This requires the deficit in that year to be below about 2½% of GDP.
- A second supplementary aim that the government must set a cap on welfare spending over the rolling 5-year forecast period.


This updated CBR has echoes of the original CBR¹, with the supplementary debt/GDP aim moving to 16/17 from 15/16. One significant change is that the target for the cyclically adjusted current balance is shortened to three years ahead from five years ahead. This is a modest improvement, because the government generally only has detailed public spending plans for roughly two years ahead, with outline plans beyond that. Hence, the shorter horizon increases the need for the government to produce detailed plans to meet the CBR targets. But the new CBR still has broadly the same weaknesses as the old one:

- The first aim (the key one) simply requires the OBR to forecast that proposed measures will achieve a cyclically adjusted current balance in a few years. Strictly speaking, the government never need actually achieve a current budget surplus – the OBR just has to be able to forecast that it will do so. The current coalition has always met this forward-looking target, even though the current budget remains in deficit and has turned out worse than previously forecast.

¹ This was published in April 2011, and set two aims: (1) cyclically-adjusted current balance by the end of the rolling, five-year forecast period; and (2) a falling debt/GDP ratio for 2015-16.


- Second, the CBR is not legally binding: there is no penalty for failure other than embarrassment. The current coalition accepted fairly early (in the end-2012 Autumn Statement or AS) that it would fail to achieve the supplementary debt aim (falling debt/GDP ratio in 15/16) and did not tighten fiscal policy to get back on track. That may well have been the correct judgment in the circumstances (EMU crisis, disappointing growth) but highlights that the government is not legally compelled to meet the CBR targets.

Figure 3. UK – OBR Forecasts for Cyclically Adjusted Current Deficit as Pct of GDP, Fiscal Years 2009/10 to 19/20



Note: Positive figure implies deficit. Sources: OBR and Citi Research

Figure 4. UK – OBR Forecasts for Net Public Debt/GDP Ratio, Fiscal Years 2009/10 to 19/20



Sources: OBR and Citi Research

Nevertheless, even with these issues, we do regard the CBR as a useful device to ensure a general commitment to fiscal sustainability within a multi-year framework. And the fact that there is now a multi-party consensus on the issue, with the Conservatives, Labour and Lib Dems all voting in favour of it, helps underpin the credibility of the UK's commitment to medium-term fiscal stability. Moreover, the need to meet the CBR targets in the next 2-3 years probably helped ensure there was no pre-election giveaway in the AS, and probably will also ensure there is no net giveaway in the pre-election 2015 Budget (18 March).

The Coalition's Fiscal Plans

The current coalition's outline fiscal plans, as published in the end-14 AS, over-achieve against the CBR targets. These plans imply a drop in the public spending share of GDP from roughly 40.5% in 14/15 to 36.9% in 17/18. On the OBR's forecasts, this is enough to achieve a falling debt/GDP ratio in 16/17 (meeting the supplementary CBR target) and a cyclically adjusted current surplus of 0.7% of GDP in 17/18 (meeting the first CBR target), with the overall fiscal deficit in 17/18 at 0.7% of GDP. The AS plans then imply a further drop in the public spending share of GDP to 35.2% in 2019/20, which for 2019/20 would produce a cyclically adjusted current surplus of 2.3% of GDP (£51bn) with an overall budget surplus of 1% of GDP (£23bn). This path would put the debt/GDP ratio on a marked downtrend, falling from 81% in 2015/16 to 73% in 19/20, with this ratio falling by 2-3 percentage points per year.

This is clearly in excess of CBR targets, which could be met by keeping the cyclically adjusted current surplus at the 0.7% of GDP level projected by the OBR for 17/18 (or even a little lower). If, for example, the coalition merely aimed to stabilize the cyclically adjusted current balance at a surplus of 0.5% of GDP for 2017/18 onwards (which is fully consistent with the CBR), then this would create

significant extra fiscal space (£4bn in 17/18, rising to £40bn in 19/20) that could be used for either higher public spending or tax cuts.

The Conservatives' Fiscal Plans

It is unclear whether the Conservatives' fiscal aim is to meet the CBR targets or to meet the tougher AS forecasts – ie outright fiscal surpluses.

There is some evidence that the Conservatives genuinely want to aim for an overall budget surplus, and not just the cyclically adjusted current surplus required by the CBR. For example, in his Royal Society Lecture², the Chancellor argued *"Indeed, the Treasury analysis we've published has found that, if you allow for regular shocks consistent with those experienced in the UK over the last 6 decades, running a balanced current budget alone would only reduce debt as a share of GDP by 5% over the next 20 years. In 2035 our debt would still be 76% of GDP. Instead, countries like Canada and Sweden have demonstrated that the only reliable way to reduce debt levels in a low inflation world is to operate some kind of balanced budget or surplus rule... So let me sum up what I'm proposing today. We need a plan to keep Britain secure. So in the good times we stay in surplus – raising more money than we spend and using that to pay down our debts. And when the bad times come, the government will have to set out a clear plan to get back to health."* The Chancellor made a similar point in both the 2014 Budget and AS speeches.

All this raises a puzzle as to why the CBR does not set a target for an outright fiscal surplus. It is possible that this reflects the compromises of coalition. The Lib Dems may be unwilling to accept the aim of a fiscal surplus in the CBR, but willing to endorse outline plans that (according to the OBR) would produce a fiscal surplus in coming years on the grounds that the AS spending figures after 2015/16 are just assumptions rather than plans and hence carry less weight.

But, it also seems likely that the Conservatives are creating room for tax cuts, in line with PM Cameron's pledge at the Conservative Party Conference³: *"I can tell you now that a future Conservative Government will raise the tax-free personal allowance from £10,500 to £12,500... we will raise the threshold at which people pay the 40p rate. It's currently £41,900... in the next Parliament we will raise it to £50,000."* The IFS costs these aims at £7.2bn⁴, and Cameron repeated these aims in the Times⁵: *"In the next parliament we plan to make £25 billion of savings while making £7.2 billion in income tax cuts."* These tax cuts are not included in the AS fiscal plans. Hence, it may be that the Conservatives do not really intend to over-achieve so much versus the CBR, but rather aim to squeeze spending enough to create scope under which a Conservative government could deliver sizeable tax cuts while meeting the CBR targets (and not achieving the surpluses forecast in the AS). Hence, we assume that this £7.2bn tax cut (0.3% of GDP) would be delivered once the CBR targets are met (2017/18 onwards according to the OBR).

The Lib Dem's Fiscal Plans

The Lib Dems support the CBR and, unlike the Conservatives, do not seek to over-achieve versus the CBR targets. As Danny Alexander said to the party conference, the Lib Dems are seeking *"a balanced budget, but allow for additional investment in productive economic infrastructure – roads, railways, broadband, housing – as long*

² 14 January 2015.

³ Speech on 1 October 2014.

⁴ Source: BBC, 1 October 2014.

⁵ 30 October 2014

as the overall debt is falling as a share of the economy... We will balance the budget as planned, do it fairly, and then allow public spending to grow as the economy grows." Consistent with the CBR, this seems to imply a target of aiming for a modest but stable current surplus (as the OBR forecast for 2017/18), without the further public spending squeeze assumed in the AS for later years.

In addition, the Lib Dems propose a £1bn rise in NHS spending, funded by higher taxes: *"we will invest a further £1bn in real terms in 2016/17, as we set out at our Autumn Conference. This will be paid for by capping pensions tax relief for the richest pensioners (saving 500m), aligning dividend tax with income tax for those earning more than £150,000 (saving £400m) and scrapping the Conservative shares for rights scheme (saving £100m)."*⁶ Moreover, the Lib Dems advocate a broadly revenue-neutral mix of a rise in the personal tax allowance to £12,500 (like the Conservatives), Mansion Tax on houses worth £2m or more (like Labour) and higher capital gains tax.

If we assume that the Lib Dems would aim for a cyclically adjusted current surplus of 0.5% of GDP (consistent with the CBR), then these plans would seem to allow extra spending versus the AS plans of £1bn for 16/17, £5bn for 17/18, rising to £41bn for 2019/20. Using the OBR's nominal GDP forecasts, this path would put the net debt/GDP ratio at 76% in 19/20, with this ratio falling by 1-2 percentage points per year.

Labour's Fiscal Plans

The Labour leadership opposed many of the spending cuts of the last few years. But, as the election approaches, they are emphasising fiscal prudence. They have voted in favour of the CBR, and endorse its targets of achieving a cyclically adjusted current balance and a falling debt/GDP ratio, including a sizeable nearterm drop in the public spending/GDP ratio. Shadow Chancellor Ed Balls has committed to a fiscally-neutral manifesto: *"So in our manifesto there will be no proposals for any new spending paid for by additional borrowing."*⁷ Moreover, his recent open letter to the Shadow Cabinet was a clear statement of fiscal rectitude: *"We will cut the deficit every year, and deliver a surplus on the current budget and falling national debt as soon as possible in the next Parliament... In the meantime you should be planning on the basis that your departmental budgets will be cut not only in 2015/16, but each year until we have achieved our promise to balance the books."*⁸

If we assume a Labour-led government would aim for a cyclically adjusted current surplus of 0.5% of GDP (consistent with the CBR targets), they would have some fiscal space from 2017/18 onwards versus the AS plans. Moreover, Labour advocate a roughly fiscally-neutral mix of a higher tax burden plus extra spending.

- Extra £2.5bn for NHS spending (Time to Care Fund) funded by a Mansion Tax (planned to raise £1.2bn), *"clamping down on tax avoidance schemes"* and *"introducing fees on tobacco companies so that they make a larger contribution towards the costs of tackling tobacco-related illness"*⁹.
- Re-introduce a (narrow) 10p income tax rate at low pay levels, funded by scrapping the Married Couples Allowance (which would yield about £0.7bn).

⁶ See <http://www.libdems.org.uk/nhs-funding-increase-8bn>.

⁷ See speech to Labour Party Conference, 22 September 2014.


⁸ See open letter of 11 December 2014.

⁹ Quotes from <http://www.labour.org.uk/issues/detail/nhs-time-to-care-fund>.

- Hike Bank Levy (raising £0.8bn) to fund increased spending on childcare.
- Hike top rate tax to 50%, reversing the cut in the 2013 Budget. It is hard to judge potential revenue gains from this. Ed Balls has suggested a £3bn gain, but the Treasury's costings of the cut to 45% indicated a cost of only £0.1bn per year. It is unclear what, if anything, these revenues would be used for.


If we assume that the Labour would aim for a cyclically adjusted current surplus of 0.5% of GDP (consistent with the CBR), then these plans would seem to allow an extra spending versus the AS plans of £3.3bn for 15/16 and 16/17, £7bn for 17/18, rising to £43bn for 2019/20. In turn, assuming that nominal GDP matches the OBR's forecasts, this would (like the Lib Dems plans) put the net debt ratio at 76% in 2019/20 (and falling by 1-2 pp per year), versus 73% in the AS plans.

Figure 5. UK – Cyclically Adjusted Current Deficit (% of GDP), 2013/14-2019/20




Note Negative figure implies surplus. We assume that the CBR targets can be met by a surplus of 0.5% of GDP for the cyclically adjusted current balance. Sources: OBR and Citi Research

Figure 6. UK – Net Public Debt/GDP Ratio, 2010/11-2019/20




Note Negative figure implies surplus. We assume that the CBR targets can be met by a surplus of 0.5% of GDP for the cyclically adjusted current balance. Sources: OBR and Citi Research

Figure 7. UK – Public Spending, £bn, Under Alternative Fiscal Policy Scenarios, £bn, 2013/14 to 2019/20



Note: We assume the Conservatives would follow the AS plans. Sources: OBR and Citi Research

Figure 8. Public Spending, Pct of GDP, Under Alternative Fiscal Policy Scenarios, £bn, 2010/11 to 2019/20



Note: We assume the Conservatives would follow the AS plans. Sources: OBR and Citi Research

Political Risks over Fiscal Policy are Modest and Not Very Different Among the Parties

In our view, despite political rhetoric, we believe the similarities between the fiscal plans of the three main parties are far greater than the differences. All three main parties' plans (such as they are) are fairly prudent and consistent with the CBR. All these parties would aim for a sharply lower public spending share in GDP, a cyclically adjusted current surplus, falling debt/GDP ratio and (at most) a low fiscal deficit. And, while a Labour government might find it politically harder than a Conservative government to squeeze spending, a Labour-led government also would find it politically easier to make up for spending slippage by tax hikes. Overall, in our view, Labour's plans do not pose a significantly greater risk to the fiscal outlook for 2015-20 than those of the Conservatives or Lib Dems. We note that the Lib Dems' fiscal aims seem much closer to Labour's than to the Conservatives, and on this issue would not pose any difficulties in forming a Labour/Lib Dem coalition.

The key difference between Labour, the Lib Dems and Conservatives is over whether to emphasise tax cuts or extra public spending once the CBR targets (cyclically adjusted current balance and falling debt/GDP ratio) have been met (hopefully in 2-3 years' time), rather than whether to implement enough fiscal consolidation to achieve aim the CBR targets. To be sure, the debt/GDP ratio would fall a little faster over the next five years with an outright fiscal surplus rather than a cyclically adjusted current surplus (and small overall deficit). But, even for 2019/20, the difference is only about 3 percentage points of GDP. Moreover, given their tax cut aims, it is not clear if a Conservative government would actually seek to deliver the fiscal surplus projected by the CBR.

Moreover, while we believe that fiscal deficit risks are probably modest under all the fiscal plans of all three parties, we do believe that either a Conservative-led government or Labour-led government would pose other significant risks. First, a Conservative-led government or Labour-led government would probably be relatively weak – a minority government or multi-party coalition -- hence potentially making it harder to stay the course on fiscal consolidation if the economy worsens or voters become discontented. Second, both a Conservative-led or Labour-led government would create other policy risks. A Labour-led government would raise uncertainties over business tax and regulation, while a Conservative-led government would raise uncertainties over the UK's EU membership, given the Conservatives' commitment to hold a referendum on the issue and the significant share of Conservative MPs who probably favour EU exit. These worries differ, but both might hit business investment and the ability of firms to plan longer term. Given this prospect – that a relatively weak government seems likely and all likely outcomes create sizeable policy risks – we suspect that UK political risk will be a recurring theme for this year.

Figure 9. Economic Indicators

| | | | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------|----------------------------------------------------------------------|------------------------------|
| Wed 21 Jan | <i>LFS Unemployment, 3-M Avg (Sep-Nov)</i> | Forecast: -30,000 QQ, 5.9% Rate | Prior: -63,000 QQ, 6.0% Rate |
| | <i>LFS Unemployment Rate, Single Month (Nov)</i> | Forecast: 5.8% | Prior: 5.9% |
| | <i>Claimant Count Unemployment (Dec)</i> | Forecast: -25,000 MM, 2.6% Rate | Prior: -26.9 MM, 2.7% Rate |
| | <i>Average Earnings Ex Bonus (Nov)</i> | Forecast: 2.2% YY, 1.9% 3-M YY | Prior: 1.8% YY, 1.6% 3-M YY |
| Surveys suggest that firms' hiring intentions remain very strong, and as a result we expect that job growth will stay high, hence producing another solid decline in the jobless rate – which we expect will fall below 6.0% for the first time since Sep-2008. There seems to be a sizeable backlog of pent-up demand for staff, with the level of job vacancies up 22% YoY and close to the precrisis peak. | | | |
| Thu 22 Jan | <i>Public Sector Net Borrowing (Dec)</i> | Forecast: £10.1bn deficit, £85.9 billion deficit fiscal year to date | |
| | <i>(Ex Public Sector Banks)</i> | Year Ago: £10.3bn deficit, £86.5 billion deficit fiscal year to date | |
| There have been signs of better revenue growth recently, with central government receipts (ex APF transfers) up 5.0% YoY in October-November, versus the gain of 2.4% YoY in April-September. As a result, the fiscal deficit has edged below year-ago levels in the last two months. We suspect this better tone will continue this month, as the benefits of economic recovery continue to feed through, with the deficit again slightly below last year's levels. | | | |
| Thu 22 Jan | <i>CBI Industrial Trends Survey (Jan)</i> | | |
| | <i>Quarterly Industrial Confidence (Jan)</i> | Forecast: +8% | Prior (Oct): +8% |
| | <i>Monthly Output Expectations Net Bal. (Jan)</i> | Forecast: +20% | Prior (Dec): +16% |
| | <i>Monthly Order Books Net Balance (Jan)</i> | Forecast: +2% | Prior (Dec): +5% |
| | <i>Monthly Selling Prices Net Balance (Jan)</i> | Forecast: +10% | Prior (Dec): +7% |
| The January CBI survey usually shows a sharp rise in the balance of firms expecting to hike selling prices, with an average figure of +15% over the last 10 years (compared to +8% for the December survey. Hence, a figure in line with our forecast would imply weakness in seasonally adjusted terms, and indeed would be the lowest January price survey since 2010. | | | |
| Fri 23 Jan | <i>Retail Sales Volumes (Dec)</i> | Forecast: -0.2% MM, 3.4% YY | Prior: 1.6% MM, 6.4% YY |
| The December retail sales tend to be relatively volatile (and indeed the retail sales figures as a whole are often volatile), and have shown a MoM decline in eight of the last 15 years (the most of any month). Given that, and the strength of the past two months, we pencil in a small decline this month. Even so, such a figure would leave Q4 volumes up 1.9% QoQ, the strongest quarter since 2004. | | | |

Source: Citi Research

Figure 10. Economic Calendar, 12 January — 30 January 2015

| 12 January | 13 January | 14 January | 15 January | 16 January |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| | Consumer Prices (Dec) Nov -0.3% MM, 1.0% YY Dec 0.0% MM, 0.5% YY CPI Ex F, D, T, E (Dec) Nov -0.1% MM, 1.2% YY Dec 0.2% MM, 1.3% YY Retail Prices (Dec) Nov -0.2% MM, 2.0% YY Dec 0.2% MM, 1.6% YY RPIX – Ex Mortgages (Dec) Nov -0.2% MM, 2.0% YY Dec 0.2% MM, 1.7% YY Producer Input Prices (Dec) Nov -0.7% MM, -8.2% YY Dec -2.4% MM, -10.7% YY Producer Output Prices (Dec) Nov -0.2% MM, -0.6% YY Dec -0.3% MM, -0.8% YY Ex F, D, T, E (Dec) Nov 0.0% MM, 0.9% YY Dec 0.0% MM, 0.8% YY | Profitability of UK Companies (Q3) | RICS House Price Survey (Dec, 00:01) Swiss National Bank: Ends Exchange Rate Cap, Cuts Rates 50bp to -0.75% | |
| 19 January | 20 January | 21 January | 22 January | 23 January |
| | | LFS Unemployment (Sep-Nov) Aug-Oct -63K QQ Sep-NovE -30K QQ LFS Unemployment Rate, 3-Month Avg (Sep-Nov) Aug-Oct 6.0% Sep-NovE 5.9% LFS Unemployment Rate, Single Month (Nov) Oct 5.9% NovE 5.8% Claimant Count Unemployment (Dec) Nov -26.9K MM, 2.7% Rate DecE -25.0K MM, 2.6% Rate Avg Earnings Ex Bonus (Nov) Oct 1.8% YY, 1.6% 3-M YY NovE 2.2% YY, 1.9% 3-M YY MPC Minutes (8 Jan) | Public Sector Net Borrowing (Ex Banks), (Dec) Dec13 £10.3bn Deficit Dec14E £10.1bn Deficit Fiscal Year To Date Apr-Dec13 £86.5bn Deficit Apr-Dec14E £85.9bn Deficit CBI Ind. Trends (Jan, 11:00) Ortly Ind. Confidence (Jan) Oct +8% JanE +8% Mthly Output Expectations Dec +16% JanE +20% Monthly Order Books (Jan) Dec +5% JanE +2% Monthly Selling Prices (Jan) Dec +7% JanE +10% ECB Monetary Policy Mtg 12:45 Outcome 13:30 Press Conference | Retail Sales Volumes (Dec) Nov 1.6% MM, 6.4% YY DecE -0.2% MM, 3.4% YY |
| 26 January | 27 January | 28 January | 29 January | 30 January |
| BBA Loans for House Purchase (Dec) <i>During The Week</i> Nationwide House Prices (Jan, 08:00) Eurogroup Meeting (Brussels) | Service Sector Output (Nov) GDP (Q4, Preliminary) EcoFin Meeting (Brussels) FOMC Meeting | FOMC Meeting | CBI Retail Survey (Jan, 11:00) | GfK Consumer Confidence (Jan, 00:01) Mortgage Approvals (Dec) |

E Citi estimate. B Billion. P Provisional. R Revised. Note: All data are released at 9.30 a.m., except those marked otherwise.
Sources: BoE, CBI, ONS, national sources and Citi Research.

Appendix A-1

Analyst Certification

The research analyst(s) primarily responsible for the preparation and content of this research report are named in bold text in the author block at the front of the product except for those sections where an analyst's name appears in bold alongside content which is attributable to that analyst. Each of these analyst(s) certify, with respect to the section(s) of the report for which they are responsible, that the views expressed therein accurately reflect their personal views about each issuer and security referenced and were prepared in an independent manner, including with respect to Citigroup Global Markets Inc and its affiliates. No part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst in this report.

IMPORTANT DISCLOSURES

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability which includes investment banking revenues.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Research product ("the Product"), please contact Citi Research, 388 Greenwich Street, 28th Floor, New York, NY, 10013, Attention: Legal/Compliance [E6WYB6412478]. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

NON-US RESEARCH ANALYST DISCLOSURES

Non-US research analysts who have prepared this report (i.e., all research analysts listed below other than those identified as employed by Citigroup Global Markets Inc.) are not registered/qualified as research analysts with FINRA. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. The legal entities employing the authors of this report are listed below:

Citigroup Global Markets Ltd

Michael Saunders; Ann O'Kelly

OTHER DISCLOSURES

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the issuer(s) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citi Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

Important Disclosures for Bell Potter Customers: Bell Potter is making this Product available to its clients pursuant to an agreement with Citigroup Global Markets Australia Pty Limited. Neither Citigroup Global Markets Australia Pty Limited nor any of its affiliates has made any determination as to the suitability of the information provided herein and clients should consult with their Bell Potter financial advisor before making any investment decision.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in **Australia** through Citigroup Global Markets Australia Pty Limited. (ABN 64 003 114 832 and AFSL No. 240992), participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in **Brazil** by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of **Canada** by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. This product is available in **Chile** through Banchile Corredores de Bolsa S.A., an indirect subsidiary of Citigroup Inc., which is regulated by the Superintendencia de Valores y Seguros. Agustinas 975, piso 2, Santiago, Chile. The Product is distributed in **Germany** by Citigroup Global Markets Deutschland AG ("CGMD"), which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). CGMD, Reuterweg 16, 60323 Frankfurt am Main. Research which relates to "securities" (as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)) is issued in **Hong Kong** by, or on behalf of, Citigroup Global Markets Asia Limited which takes full responsibility for its content. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Research is made available through Citibank, N.A., Hong Kong Branch, for its clients in Citi Private Bank, it is made available by Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citibank N.A. is regulated by the Hong Kong Monetary Authority. Please contact your Private Banker in Citibank N.A., Hong Kong, Branch if you have any queries on or any matters arising from or in connection with this document. The Product is made available in **India** by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. 1202, 12th Floor, FIFC, G Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051 Corporate Identity Number: U99999MH2000PTC126657 Tel:+9102261759999 Fax:+9102261759961. The Product is made available in **Indonesia** through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. The Product is made available in **Israel** through Citibank NA, regulated by the Bank of Israel and the Israeli Securities Authority. Citibank, N.A., Platinum Building, 21 Ha'arba'ah St, Tel Aviv, Israel. The Product is made available in **Italy** by Citigroup Global Markets Limited, which is authorised by the PRA and regulated by the FCA and the PRA. Via dei Mercanti, 12, Milan, 20121, Italy. The Product is made available in **Japan** by Citigroup Global Markets Japan Inc. ("CGMJ"), which is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. If the Product was distributed by SMBC Nikko Securities Inc. it is being so distributed under license. In the event that an error is found in an CGMJ research report, a revised version will be posted on the Firm's Citi Velocity website. If you have questions regarding Citi Velocity, please call (81 3) 6270-3019 for help. The Product is made available in **Korea** by Citigroup Global Markets Korea Securities Ltd., which is regulated by the Financial Services Commission, the Financial Supervisory Service and the Korea Financial Investment Association (KOFIA). Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. KOFIA makes available registration information of research analysts on its website. Please visit the following website if you wish to find KOFIA registration information on research analysts of Citigroup Global Markets Korea Securities Ltd. <http://dis.kofia.or.kr/websquare/index.jsp?w2xPath=/wq/fundMgr/DISFundMgrAnalystList.xml&divisionId=MDIS03002002000000&serviceId=SDIS030020020000>. The Product is made available in Korea by Citibank Korea Inc., which is regulated by the Financial Services Commission and the Financial Supervisory Service. Address is Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. The Product is made available in **Malaysia** by Citigroup Global Markets Malaysia Sdn Bhd (Company No. 460819-D) ("CGMM") to its clients and CGMM takes responsibility for its contents. CGMM is regulated by the Securities Commission of Malaysia. Please contact CGMM at Level 43 Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur, Malaysia in respect of any matters arising from, or in connection with, the Product. The Product is made available in **Mexico** by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, Integrante del Grupo Financiero Banamex ("Accival") which is a wholly owned subsidiary of Citigroup Inc. and is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In **New Zealand** the Product is made available to 'wholesale clients' only as defined by s5C(1) of the Financial Advisers Act 2008 ('FAA') through Citigroup Global Markets Australia Pty Ltd (ABN 64 003 114 832 and AFSL No. 240992), an overseas financial adviser as defined by the FAA, participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in **Pakistan** by Citibank N.A. Pakistan branch, which is regulated by the State Bank of Pakistan and Securities Exchange Commission, Pakistan. AWT Plaza, 1.1. Chundrigar Road, P.O. Box 4889, Karachi-74200. The Product is made available in the **Philippines** through Citicorp Financial Services and Insurance Brokerage Philippines, Inc., which is regulated by the Philippines Securities and Exchange Commission. 20th Floor Citibank Square Bldg. The Product is made available in the Philippines through Citibank NA Philippines branch, Citibank Tower, 8741 Paseo De Roxas, Makati City, Manila. Citibank NA Philippines NA is regulated by The Bangko Sentral ng Pilipinas. The Product is made available in **Poland** by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Nadzoru Finansowego. Dom Maklerski Banku Handlowego S.A. ul.Senatorska 16, 00-923 Warszawa. The Product is made available in the **Russian Federation** through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in **Singapore** through Citigroup Global Markets Singapore Pte. Ltd. ("CGMSPL"), a capital markets services license holder, and regulated by Monetary Authority of Singapore. Please contact CGMSPL at 8 Marina View, 21st Floor Asia Square Tower 1, Singapore 018960, in respect of any matters arising from, or in connection with, the analysis of this document. This report is intended for recipients who are

accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore Branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Please contact your Private Banker in Citibank N.A., Singapore Branch if you have any queries on or any matters arising from or in connection with this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). This report is distributed in Singapore by Citibank Singapore Ltd ("CSL") to selected Citigold/Citigold Private Clients. CSL provides no independent research or analysis of the substance or in preparation of this report. Please contact your Citigold/Citigold Private Client Relationship Manager in CSL if you have any queries on or any matters arising from or in connection with this report. This report is intended for recipients who are accredited investors as defined under the Securities and Futures Act (Cap. 289). Citigroup Global Markets (Pty) Ltd. is incorporated in the **Republic of South Africa** (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in the **Republic of China** through Citigroup Global Markets Taiwan Securities Company Ltd. ("CGMTS"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan and/or through Citibank Securities (Taiwan) Company Limited ("CSTL"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan, subject to the respective license scope of each entity and the applicable laws and regulations in the Republic of China. CGMTS and CSTL are both regulated by the Securities and Futures Bureau of the Financial Supervisory Commission of Taiwan, the Republic of China. No portion of the Product may be reproduced or quoted in the Republic of China by the press or any third parties [without the written authorization of CGMTS and CSTL]. If the Product covers securities which are not allowed to be offered or traded in the Republic of China, neither the Product nor any information contained in the Product shall be considered as advertising the securities or making recommendation of the securities in the Republic of China. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security or financial products. Any decision to purchase securities or financial products mentioned in the Product must take into account existing public information on such security or the financial products or any registered prospectus. The Product is made available in **Thailand** through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 399 Interchange 21 Building, 18th Floor, Sukhumvit Road, Klongtoey Nua, Wattana, Bangkok 10110, Thailand. The Product is made available in **Turkey** through Citibank AS which is regulated by Capital Markets Board. Tekfen Tower, Eski Büyükdere Caddesi # 209 Kat 2B, 23294 Levent, Istanbul, Turkey. In the **U.A.E.**, these materials (the "Materials") are communicated by Citigroup Global Markets Limited, DIFC branch ("CGML"), an entity registered in the Dubai International Financial Center ("DIFC") and licensed and regulated by the Dubai Financial Services Authority ("DFSA") to Professional Clients and Market Counterparties only and should not be relied upon or distributed to Retail Clients. A distribution of the different Citi Research ratings distribution, in percentage terms for Investments in each sector covered is made available on request. Financial products and/or services to which the Materials relate will only be made available to Professional Clients and Market Counterparties. The Product is made available in **United Kingdom** by Citigroup Global Markets Limited, which is authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA. This material may relate to investments or services of a person outside of the UK or to other matters which are not authorised by the PRA nor regulated by the FCA and the PRA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in **United States** by Citigroup Global Markets Inc, which is a member of FINRA and registered with the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is authorised by the PRA and regulated by the FCA and the PRA. Pursuant to Comissão de Valores Mobiliários Rule 483, Citi is required to disclose whether a Citi related company or business has a commercial relationship with the subject company. Considering that Citi operates multiple businesses in more than 100 countries around the world, it is likely that Citi has a commercial relationship with the subject company.

Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Research's Products can be found at https://www.citivelocity.com/cvr/epublic/citi_research_disclosures.

Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations.

The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted.

Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product. Citi Research generally disseminates its research to the Firm's global institutional and retail clients via both proprietary (e.g., Citi Velocity and Citi Personal Wealth Management) and non-proprietary electronic distribution platforms. Certain research may be disseminated only via Citi's proprietary distribution platforms; however such research will not contain changes to earnings forecasts, target price, investment or risk rating or investment thesis or be otherwise inconsistent with the author's previously published research. Certain research is made available only to institutional investors to satisfy regulatory requirements. Individual Citi Research analysts may also opt to circulate published research to one or more clients by email; such email distribution is discretionary and is done only after the research has been disseminated.

The level and types of services provided by Citi Research analysts to clients may vary depending on various factors such as the client's individual preferences as to the frequency and manner of receiving communications from analysts, the client's risk profile and investment focus and perspective (e.g. market-wide, sector specific, long term, short-term etc.), the size and scope of the overall client relationship with Citi and legal and regulatory constraints. Citi Research product may source data from dataCentral. dataCentral is a Citi Research proprietary database, which includes Citi estimates, data from company reports and feeds from Thomson Reuters. The printed and printable version of the research report may not include all the information (e.g., certain financial summary information and comparable company data) that is linked to the online version available on Citi's proprietary electronic distribution platforms.

© 2015 Citigroup Global Markets Inc. Citi Research is a division of Citigroup Global Markets Inc. Citi and Citi with Arc Design are trademarks and service marks of Citigroup Inc. and its affiliates and are used and registered throughout the world. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure of this report (the "Product"), including, but not limited to, redistribution of the Product by electronic mail, posting of the Product on a website or page, and/or providing to a third party a link to the Product, is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient to any third party. Where included in this report, MSCI sourced information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, disseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST
